Drugs / LYL797
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05274451 | Mar 2022 → Nov 2024 | endometrial cancer, endometrioid tumor, fallopian tube carcinoma, female breast carcinoma +5 | Lyell Immunopharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYL797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05274451 ↗ |
| Modality | Cell therapy | “ROR1-targeted CAR T-cell therapy” NCT05274451 ↗ |
| Target | ROR1 | “ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy” NCT05274451 ↗ |